OncoMatch

OncoMatch/Clinical Trials/NCT07707232

Large Language Model-Assisted cTNM Annotation From Chinese PSMA PET/CT Reports

Official title: Large Language Model-Assisted Imaging cTNM Staging Annotation and Uncertainty Recognition for Prostate Cancer Based on Chinese PSMA PET/CT Reports

Is NCT07707232 recruiting? Yes, currently enrolling (Oct 2026).

RecruitingFirst Affiliated Hospital of Wenzhou Medical UniversityNCT07707232Data as of Oct 2026Location: China

This observational study will develop and validate a large language model-assisted workflow for imaging cTNM staging annotation and uncertainty recognition in prostate cancer using Chinese PSMA PET/CT report texts generated during routine clinical care. The study will use de-identified report texts and necessary baseline clinical information only. No additional imaging examination, blood test, treatment, or follow-up visit will be assigned for this study. The main objective is to evaluate whether a locally or institutionally controlled large language model can identify report-derived imaging cT, cN, and cM categories, extract supporting evidence from the original report, and recognize uncertainty expressions. Model performance will be assessed using an internal independent validation set, external validation reports from two collaborating hospitals, and a prospective validation set of 100 consecutive routine PSMA PET/CT reports. A human-AI comparison will also be performed using physicians from urology and imaging-related specialties with different seniority levels.

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Demographics

Male only

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT07707232 currently recruiting?

Yes, this trial is currently recruiting patients.

Is this trial open to female patients?

No. This trial enrolls male patients only.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify